The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options
UK Prime Minister Keir Starmer praised the initiative, saying: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements."
The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
Company to launch product after the expiry of semaglutide patent in India
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
Subscribe To Our Newsletter & Stay Updated
